A: Thank you so much for taking the time to ask this question—it’s a really great one! We always appreciate the creative and insightful ideas that come from the AppSumo community. Questions like this help us think about how we can continue improving Sterling Stock Picker for all our users.

Currently, our platform does not evaluate biotech stocks specifically based on their phase of trials. However, this is a very intriguing idea, and we will be discussing with our engineering team the possibility of integrating this type of data, potentially from SEC filings, into our system. We’re also excited about how this could enhance our FinleyAI recommendations and provide even deeper insights for our users.

Your feedback is incredibly valuable, and we truly appreciate the time you’ve spent sharing this suggestion. We’ll definitely explore ways to make this a part of our future updates.

Wishing you a Happy New Year and great success in 2025!